The invention generally provides compositions and methods of treating or preventing an arenavirus infection, using an agent that inhibits binding of an arenavirus glycoprotein 1 (GP1) polypeptide to transferrin receptor 1 (TfR1). The invention also provides methods of designing or identifying therapeutic agents that bind to or target a GP1 receptor-binding site (RBS) to inhibit arenavirus attachment to a cell, and therapeutic agents identified using the methods.

This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

The present invention is directed to methods and compositions for norovirus therapeutics, such as vaccines, and diagnostics.

Alternative antibodies to screen for SARS-CoV-2 are disclosed. One alternative antibody is Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1056 (“E3-Antibody” or “E3”), from EastCoast Bio, Inc., PO Box 489, North Berwick, Me. 03906, USA (“EastCoast Bio”). Another alternative antibody is a combination of the E3-Antibody and Mouse Species Coronavirus (COVID-19, MERS, and SARS-CoV NP) Antibody, Catalog Number HM1057 (“E1-Antibody” or “E1”), from EastCoast Bio (the combination of the E1-Antibody and the E3-Antibody is designated as “E1/E3-Antibody” or simply “E1/E3”). Yet another alternative antibody is a combination of Mouse Species Anti-SARS-CoV-2 NP mAb, clone 4B21, Catalog Number CABT-CS027 (“C4-Antibody” or “C4”), from Creative Diagnostics, 45-1 Ramsey Road, Shirley, N.Y. 11967, USA (“Creative Diagnostics”), and Mouse Species Anti-SARS-CoV-2 NP mAb, clone 7G21, Catalog Number CABT-CS026 (“C5-Antibody” or “C5”), also from Creative Diagnostics (the combination of the C4-Antibody and the C5-Antibody is designated as “C4/C5-Antibody” or simply “C4/C5”).

A chiral metamaterial absorber modeled after the yin-yang symbol comprising: a top yin-yang shaped Au nanoparticles (YNPs); a PMMA layer; an Au backreflector; and a bottom glass layer. In alternative embodiments, provided are devices acting as sensors for detecting a nucleotide such as a cDNA and/or a protein such as a protein from a pathogen such as a bacteria or a virus, wherein the cDNA or protein can be derived from a Coronavirus, for example, a SARS CoV-2 or COVID-19 virus. In alternative embodiments, devices acting as sensors as provided herein can also be used to detect any protein for diagnostic or therapeutic purposes, wherein the protein can be derived from a blood or plasma sample, or a tissue sample, for example, a biopsy, from an individual in need thereof, for example, a human or an animal.

The present invention provides a lateral flow test device for detecting a coronavirus antibody by immunoassay; the test device includes three lateral flow test strips; a first test strip is directed to the antibody detection of a N full-length protein and/or an S full-length protein antigens/antigen; and a second test strip is directed to the antibody detection of an S-RBD-site protein antigen, and both of the first strip and the second strip are combined to detect novel coronavirus IgG and IgM antibodies, which can practically reduce the possibility of missing detection and wrong detection; further, a third test strip is directed to the detection of a neutralizing antibody at an S-RBD site to rapidly detect the neutralizing antibody having protection effect, thus further helping the prevention of missing detection and helping patients to perform self-detection and judge the situations of recovery, or vaccine immunity.

This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.

Embodiments described herein may be useful in the detection of analytes. The systems and methods may allow for a relatively simple and rapid way for detecting analytes such as chemical and/or biological analytes and may be useful in numerous applications including sensing, food manufacturing, medical diagnostics, performance materials, dynamic lenses, water monitoring, environmental monitoring, detection of proteins, detection of DNA, among other applications. For example, the systems and methods described herein may be used for determining the presence of a contaminant such as bacteria (e.g., detecting pathogenic bacteria in food and water samples which helps to prevent widespread infection, illness, and even death). Advantageously, the systems and methods described herein may not have the drawbacks in current detection technologies including, for example, relatively high costs, long enrichment steps and analysis times, and/or the need for extensive user training. Another advantageous feature provided by the systems and methods described herein includes fabrication in a relatively large scale. In some embodiments, the systems and methods may be used in conjunction with a detector including handheld detectors incorporated with, for example, smartphones (e.g., for the on-site detection of analytes such as pathogenic bacteria).

Provided herein are methods and systems for detecting coronavirus. Methods and systems as described herein comprise using antibodies with improved specificity and sensitivity for accurately detecting coronavirus.

The present invention relates to a screen protection cover configurable on a handheld device (E.g., a smartphone). The cover includes a transparent cover body, an adhesive member and a chemical agent(s). The transparent body is configured to cover a display screen of the handheld device. The adhesive member is provided on a rear surface of the cover for removably attaching the cover onto a front surface of the display screen of the handheld device. The chemical agent is adapted to change its physical property to alert the user about a potential infection when one or more biological agents transmitted from the user's body come in contact or in proximity to the cover. The physical property includes a color and/or a smell. The user is required to conduct a medically proven disease diagnosis test upon receiving a visible or sensory alert generated by the cover.